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Purpose: To define prognostic factors associated with improved survival and local 
control (LC) for gynecologic cancer recurrences limited to the pelvis and para-aortic (PA) 
region using stereotactic body radiation therapy (SBRT).
Methods: Between 2/2008 and 7/2014, 30 women (35 targets) with pelvic or PA recur-
rence of endometrioid (n = 12), cervical (n = 11), ovarian (n = 3), uterine-serous (n = 2), 
or carcinosarcoma (n =  2) cancer were treated with SBRT. Eleven recurrences were 
located in the central pelvis, 11 along the pelvic sidewall (PSW), and 13 in the PA region.
results: Five-year survival for all patients was 42% with a median survival of 43.4 months. 
Multivariate analysis revealed better performance status (PS), and smaller clinical tumor 
volume was significant for improved survival (p < 0.05).
conclusion: SBRT is a local therapy for recurrent gynecological malignancies in the 
pelvis and PA region with curative potential. SBRT is especially effective for LC when 
targeting PSW or PA recurrence and for patients with a cervical/endometrioid uterine 
primary. Survival is improved for patients with better PS and smaller recurrence volume 
prior to SBRT.
Keywords: gynecological malignancies, stereotactic body radiation therapy, endometrial neoplasms, uterine 
cervical neoplasms, ovarian neoplasms, uterine neoplasms
inTrODUcTiOn
An estimated 30–40% of gynecological malignancies recur after initial treatment, leaving many 
patients with a poor prognosis and limited treatment options (1). Regional failures of endome-
trial, cervical, and ovarian cancer frequently include areas of prior radiation therapy (RT) used for 
initial treatment such as pelvic sidewall (PSW) and para-aortic (PA) lymph node regions (2). As 
such, potential morbidity does not permit re-irradiation at effective doses with conventional tech-
niques. Alternatively, central pelvic recurrences can be treated surgically; however, many patients 
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are inoperable in particular those with nodal recurrences. 
Chemotherapy has proven to be a less effective salvage treatment 
with limited palliation and no chance for long-term survival. 
Stereotactic body radiation therapy (SBRT) is emerging as an 
attractive primary option for recurrent tumors in the pelvis and 
PA region, because the highly conformal and precise radiation 
delivery offers a local non-surgical salvage option, even in the 
setting of re-irradiation (3).
Several retrospective series have reported pelvic exentera-
tion and lymph node dissection as an option for highly selected 
patients with local gynecologic recurrence (4). However, survival 
data widely varies and the procedures are morbid, with grades 
3–5 post-operative complications as high as 44% (5). For inoper-
able patients, local and pelvic lymph node recurrences have been 
treated with conventional external beam radiotherapy (EBRT) 
to the pelvis, with or without abdominal radiation and systemic 
therapy. In the setting of prior pelvic irradiation, intensity modu-
lated radiotherapy is often employed in order to limit dose to 
previous treatment fields, though the total dose is still limited. 
Ablative doses in the re-irradiation setting can be reached with 
brachytherapy; however, recurrence must be at the vaginal cuff. 
Like surgery, the outcomes from retrospective series of EBRT and 
brachytherapy are inconsistent, likely due to selection bias (6–9). 
Chemotherapy alone is typically reserved as palliation for meta-
static disease or in combination with surgery or radiation with 
curative intent for locoregional recurrences. In either scenario, 
platinum-based systemic therapy is typically used alone or in 
combination with other agents (10–14).
Potentially curative therapy with radiation for pelvic and PA 
recurrence after initial therapy has been limited to patients not 
previously irradiated due to the potential toxicity to organs at risk 
(OAR) including bowel and bladder by exceeding tolerance doses 
to these organs. SBRT potentially minimizes this toxicity by pre-
cise tracking of the tumor with tight margins which allows high 
doses of radiation to be delivered to the target while relatively 
sparing nearby OAR that received prior RT. For those patients 
who have not received previous radiation, SBRT may be even 
more effective since it can be used as a boost with EBRT with 
implant-like dose distribution for difficult to implant areas such 
as PSW and PA recurrences. Among the technology equipped 
to deliver stereotactic radiotherapy, CyberKnife (Accuray Inc., 
Sunnyvale, CA, USA) is a robotic radiosurgery system in which 
a compact 6 MV photon linear accelerator mounted on a robotic 
arm delivers hundreds of radiation beamlets to the target from 
different angles as designed by the planning computers. A high 
intensity dose is delivered to the tumor and the dose to the sur-
rounding tissue falls off faster than with conventional radiation. 
The system takes a pair of orthogonal X-ray images every three 
to five beams during SBRT to track the target’s position and the 
robot will compensate for the target’s motion to achieve overall 
precision of 1 mm or better. The sub-mm precision allows tighter 
margins than conventional radiation (15), and is well suited for 
re-irradiation, as previous prospective trials demonstrated no 
increased toxicity when SBRT was delivered to sites previously 
treated with conventional RT (16–18).
Evidence suggests that an SBRT boost is a viable alternative 
to brachytherapy boost for patients with primary cervical or 
endometrial tumors who were not amenable to brachytherapy 
(19,  20). Recurrences treated with SBRT are described in the 
literature, albeit with a small or heterogenous patient population. 
Some studies combine the results of primary and recurrent tumors 
(21, 22), others include non-gynecologic primaries (23–26), and 
some have less than 10 patients (27–29). Guckenberger et  al. 
reported an 81% 3-year local control (LC) rate and median 
overall survival of 25  months in (mostly central) pelvic recur-
rences treated with EBRT and an SBRT boost (30). We report our 
single institutional experience of SBRT for recurrent gynecologic 
malignancies in the pelvic and PA region to explore the rate of 
long-term LC that may ultimately translate into a potential cure.
MaTerials anD MeThODs
Patient characteristics
Between February 2008 and July 2014, 30 patients (35 lesions) 
were treated with SBRT for gynecologic malignancies with 
locoregional recurrence in either the central pelvis (CP), along 
the PSW, or para-aortic nodes (PAN) in this IRB approved 
study. Recurrences were diagnosed by pelvic exam, computed 
tomography (CT), magnetic resonance imaging (MRI), and/
or positron emission tomography (PET)–CT. Every patient 
had radiographic follow-up at least 3  months after treatment 
with SBRT. Palliative and metastatic patients were excluded 
from the study. The median age was 70 years old (37–89) and 
median time to recurrence from initial diagnosis was 28 months 
(3–507 months). Targets included 13 PAN, 11 CP, and 11 PSW 
recurrences. Of the 30 women, 12 had endometrioid adenocar-
cinoma of the uterus, 11 squamous cell carcinoma of the cervix, 
3 papillary serous adenocarcinoma of the ovary, 2 papillary 
serous adenocarcinoma of the uterus, and 2 carcinosarcoma 
(mixed Mullerian tumor) of the uterus. The median tumor size 
was 3.3 cm, ranging from 0.9 to 9.1 cm. Fifteen of the 35 recur-
rences were in areas previously irradiated as part of the initial 
treatment. Twenty-four of 30 patients received surgery for their 
initial treatment and 9 received chemotherapy. Platinum-based 
chemotherapy was used as salvage therapy in conjunction with 
SBRT in 13 of 29 patients (unknown n = 1). The median follow-
up duration was 24  months (5–92  months). A summary of 
patient characteristics and treatment is summarized in Table 1.
sBrT Treatment
Nine of the 35 lesions were treated with EBRT followed by an 
SBRT boost to gross tumor volume (GTV) and the remaining 
26 targets were treated with SBRT alone, 15 of which could not 
receive EBRT as salvage therapy because of previous irradiation. 
GTV = clinical tumor volume (CTV) ranged from 0.9 to 285.3 cc 
(median 29.8  cc) and the median SBRT dose for all patients 
was 27.5 Gy (15–40 Gy) in three to five fractions (median five 
fractions). Patients who received EBRT with an SBRT boost for 
recurrent tumors received a biological equivalent dose (BED) of 
72.6–112.8 Gy (median 81.1 Gy) to the target lesions, whereas the 
BED for patients who only received SBRT received 35.7–72 Gy 
(median 48  Gy). Dose was prescribed to the 60–74% (median 
69%) isodose line.
TaBle 1 | Patient and treatment characteristics.
Pt no Tumor 
no
age initial Dx location  
of rec
Time to  
rec (mo)
cTV  
(cc)
chemo  
for rec
Previous  
XrT
sBrT 
delivery
Total  
BeD gy10d
local  
control
survival grade  
3/4 Tox
F/U  
(mo)
1 1 58 Ovarian-serous PSW 28 52.9 No No CK only 59.5 LR Death No 17
2 2 70 Endometrial Central 19 29.1 Yes No CK boost 81.1 LR Death No 15
3 3 83 Endometrial PA 15 32.8 No Yes CK only 35.7 LC Death No 6
4 4 82 Endometrial PA 38 12.7 Yes No CK only 72 LC Alive No 92
5 5 80 Cervical PSW 3 0.91 No No CK boost 112.8 LC Death No 19
6 6 40 Cervical Central 28 9.4 Yes No CK boost 83.7 LC Alive No 24
7 7 72 Cervical Central 78 29.8 Yes No CK boost 90.6 LC Alive Noa 45
8 8 82 Cervical Central 507 285.3 No Yes CK only 48 LC Death No 5
9 9 68 Ovarian-clear cell PSW 54 30 No No CK only 42.6 LC Death No 29
10 10 79 Cervical PSW 15 68.3 No Yes CK only 48 LC Death No 7
11 11 37 Cervical Central 29 88.8 Yes Yes CK only 37.5 LC Alive Yesb 21
12 12 64 Endometrial PSW 18 8.3 No No CK boost 75.6 LC Alive Noc 77
13 13 72 Endometrial PA 6 1.8 No No CK boost 81.1 LC Alive No 57
14 14 62 Endometrial PA 3 30.7 No No CK only 37.5 LC Death No 63
– 15 62 Endometrial PA 3 8.4 No No CK only 37.5 LC Death No –
15 16 71 Cervical PA 10 8.3 Yes No CK only 65.6 LC Alive No 63
16 17 70 Endometrial PA 5 103.5 Yes No CK boost 72.6 LC Alive No 60
– 18 73 Endometrial PA 45 7.7 No Yes CK only 65.6 LC Alive No –
17 19 76 Carcinosarcoma Central 14 14.9 No Yes CK only 59.5 LR Alive No 23
18 20 80 Endometrial Central 10 85.7 Yes Yes CK only 37.5 LC Death No 11
19 21 80 Cervical Central 34 8.3 – No CK boost 98 LC Alive No 8
20 22 89 Uterine-serous PA 34 24 No No CK only 72 LR Death No 16
– 23 89 Uterine-serous PA 38 8.7 No No CK only 48 LR Death No –
21 24 65 Carcinosarcoma PA 35 31.2 Yes No CK only 37.5 LC Alive No 22
22 25 60 Uterine-serous Central 47 50 No Yes CK only 48 LR Death No 14
– 26 60 Uterine-serous Central 47 11.4 No Yes CK only 48 LR Death No –
23 27 89 Endometrial PSW 229 38.4 No Yes CK only 72 LC Death No 43
24 28 79 Endometrial Central 25 15.7 No Yes CK only 59.5 LR Alive No 29
25 29 66 Ovarian-serous PSW 80 4.7 Yes No CK only 48 LR Alive No 47
26 30 59 Endometrial PSW 153 43.6 Yes No CK boost 81.1 LC Alive No 64
27 31 52 Cervical PSW 3 36.7 No Yes CK only 43.2 LC Death No 59
– 32 52 Cervical PSW 3 36.7 No Yes CK only 43.2 LC Death No –
28 33 56 Cervical PA 30 67.3 Yes Yes CK only 53.6 LC Alive No 17
29 34 60 Endometrial PSW 98 86.5 Yes Yes CK only 48 LC Alive No 10
30 35 66 Cervical PA 21 7.9 No No CK only 48 LC Death No 26
Pt, patient; No, number; Dx, diagnosis; rec, recurrence; mo, months; CTV, clinical target volume; cc, cubic centimeters; Chemo, chemotherapy; BED, biological equivalent dose; XRT, radiotherapy; Tox, toxicity; PA, para-aortic; PSW, 
pelvic sidewall; CK, cyberknife; LC, local control; LR, local recurrence; F/U, follow-up.
aGrade 2 radiation cystitis.
bGrade 3 rectovaginal/vaginovesicular fistulas.
cGrade 2 proctitis.
dIncludes all radiation delivered for recurrence which includes SBRT alone dose or external beam + SBRT combined doses if boost used.
–, unknown if chemotherapy delivered.
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FigUre 1 | continued
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Tumors were tracked with fiducials (n = 23) or X-site spine 
tracking algorithm (n = 12). The GTV was defined as visible 
tumor on CT with oral and IV contrast, MRI, and PET–CT 
with images merged for target definition. The planning target 
volume (PTV) included the GTV and typically a 3-mm margin 
(range 0–5 mm) except at critical contiguous structures such as 
bowel or the aorta. A pair of orthogonal X-rays were acquired 
during the setup, and aligned with DRR (digital radiographs 
reconstructed from the planning CTs) using spine/hip or fidu-
cial as match landmark. Based on the alignment, the treatment 
FigUre 1 | (a) Kaplan–Meier survival curve for all patients. (B) Kaplan–Meier local control curve for all recurrences treated with SBRT. (c) Kaplan–Meier disease-
free survival curve for all patients.
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table is remotely moved to shift patient to the desired treatment 
position and new X-ray taken to verify an appropriate match 
prior the treatment. Once treatment starts, X-rays are taken 
every three to five beams throughout treatment delivery and 
robot will offset linac position based on the X-rays alignment 
to track patient’s position and achieve optimal targeting preci-
sion. Our Cyberknife treatment uses 57–201 (median 145) 
non-isocentric 6-MV photon beams to irradiate a single target 
stereotactically.
assessment of results
All patients had at least 3 months of radiographic follow-up with 
pelvic exam and most recent imaging within at least 6 months 
of the latest clinical follow-up. Local recurrence after salvage 
therapy was defined as a lesion that developed within the SBRT 
PTV. Any tumor that appeared outside the radiation target, 
including non-irradiated PSW or PANs were considered distant 
failures. Radiation-induced toxicity was based on the Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0, 
and attributed to RT if the toxic event occurred in the absence 
of progressive disease (31). Overall survival and LC estimates for 
the total cohort were generated using log-rank Kaplan–Meier 
methodology, with survival and LC comparisons based on 
the Wilcoxon method. Unadjusted and adjusted multivariate 
hazard ratios for prognostic factors were estimated using Cox 
Proportional Hazard modeling. All statistics were generated via 
MedCalc software, version 16.8.
resUlTs
survival
The 5-year OS for all patients was 42%, with a median overall 
survival of 43.3 months. At last follow-up, 16 of 30 (53%) patients 
were alive. At 1, 2, 3, and 4 years, the OS was 85, 69, 56, and 49%, 
respectively (Figure 1A).
Multivariate analysis revealed ECOG performance status 
(PS) and CTV to be independent prognosticators for survival. 
ECOG PS of 0 yielded a 2-year survival rate of 86%, compared 
to 77% for ECOG 1 and 33% for ECOG 2 (p = 0.01). CTV less 
than 24 cc yielded 2-year survival of 86 vs. 53% for greater than 
24 cc (p = 0.005). A full list of prognostic factors with associated 
KM curves for statistically significant variables in multivariable 
analysis is reflected in Table 2 and Figure 2.
local control
Nine of 35 lesions (26%) failed locally, resulting in LC rates of 
80 and 73% at 1 and 2 years, respectively. The 3-year and 5-year 
LC rates were 73 and 67%, respectively, and median LC could 
not be calculated due to an inadequate number of recurrences 
(Figure  1B). Ovarian/non-endometrioid uterine cancers com-
pared to endometrioid uterine/cervical primaries and CP com-
pared to PSW/PAN recurrences were associated with poorer LC. 
The 2-year LC rate of cervical, endometrioid uterine, and ovar-
ian/non-endometrioid uterine recurrences was 100, 82, and 33, 
respectively. Five of the 11 cervical cancers were re-irradiated. At 
TaBle 2 | Univariate analysis: survival hazard ratios (N = 30).
Prognostic factors N survival hr (95% ci) p-Value
Serous/clear cell/carcinosarcoma 7 1.68 (0.5–1.6) 0.4
Cervical/endometrioid 23
SBRT alonea 22 2.60 (0.58–11.5) 0.16
SBRT boost 9
Re-irradiationb 13 2.67 (0.88–8.13) 0.08
No re-irradiation 18
ECOG 2 8 11.0 (1.63–71.4) 0.01
ECOG 0 8
ECOG 2 8 4.20 (1.25–14.1) 0.02
ECOG 1 14
Central pelvis 10 1.55 (0.46–5.27) 0.48
PA/PSW LN 20
CTV ≥ 24 cc 18 4.69 (1.14–19.3) 0.03
CTV < 24 cc 12
Time to recurrence ≥ 28 mo 15 1.37 (0.47–3.96) 0.56
Time to recurrence < 28 mo 15
Age ≥ 70 15 0.62 (0.21–1.78) 0.37
Age < 70 15
Age ≥ 79 10 3.33 (1.16–9.57) 0.03
Age < 79 20
BED < 53.6 Gy 15 3.21 (1.07–9.61) 0.04
BED ≥ 53.6 Gy 15
Chemo for relapse 13 2.88 (0.96–8.64) 0.06
No chemo for relapse 16
Prior chemo 9 1.98 (0.61–6.43) 0.16
No prior chemo 21
CP, central pelvis; PA, para-aortic; PSW, pelvic sidewall; SBRT, stereotactic body 
radiation therapy; N, number of patients; HR, hazard ratio; CI, confidence interval.
Bold indicates statistical significance; italics indicate a trend toward statistical 
significance.
aOne patient had both a boost and CK alone treated for two separate recurrences.
bOne patient had one site that received external and SBRT boost and another site 
treated within a previously treated external beam field.
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3 years, 40% of CP compared with 83% of PAN and 90% of PSW 
recurrences were locally controlled (Figures 3A,B). CP location 
(HR =  4.78, P =  0.02) and ovarian/non-endometrioid uterine 
cancers (HR = 14.12, P = 0.002) were each poor prognosticators 
for LC per multivariate analysis, with type of primary having a 
greater influence. A complete list of hazard ratios for potential 
correlates of LC is portrayed in Table 3.
In addition to seven patients with local failures, seven others 
developed distant failures following SBRT (47%). The resulting 
median DFS was 47 months with 1-, 2-, and 3-year DFS of 78, 61, 
and 52%, respectively (Figure 1C). Distant failure sites include 
lung (n = 2), liver (n = 2), bone (n = 1), PAN (n = 1), and PSW 
(n = 1). Five of the seven distant failures were cervical cancers, 
one was endometrial, and one was ovarian. No factors were 
significant for DFS with p ≤ 0.05 in multivariate analysis.
Toxicity
Grade 2 radiation proctitis occurred in one patient 25  months 
after completing SBRT. Argon beam coagulation therapy was 
required to treat the rectal bleeding and the patient has been 
asymptomatic at last follow-up, over 4 years since presentation of 
rectal bleeding. She received 45 Gy EBRT to the pelvis followed 
by 14.4 Gy EBRT to the right PSW followed by an SBRT boost to 
the PSW target of 15 Gy in three fractions. Her rectum received 
max dose of 54  Gy with external beam radiation and a max 
dose of 5.2 Gy with SBRT. One patient with 6 cm supravaginal 
recurrence of carcinoma in situ of the cervix (both squamous and 
adenocarcinoma histologies) treated initially with hysterectomy 
endured grade 2 cystitis with hematuria 2 years after SBRT, which 
resolved without intervention. She received 45 Gy EBRT to the 
pelvis and a subsequent SBRT boost of 25  Gy in five fractions 
to the GTV located in a supravaginal/cuff position posterior to 
the bladder measuring 29.8 cc. The volume of bladder treated by 
EBRT was 375 cc to a mean dose of 45.5 Gy and max dose of 
48.3 Gy, followed by a mean and max dose of 4.4 and 26.3 Gy with 
SBRT. She is 21 months from additional episodes of hematuria.
Another cervical cancer patient who was initially treated with 
surgery and adjuvant chemoradiation received SBRT and gemzar/
cisplatin for a central recurrence and subsequently developed 
grade 3 rectovaginal and vesicovaginal fistulas 3  months after 
treatment requiring urinary and bowel divertions. Exam under 
anesthesia initially demonstrated no pelvic mass but biopsies 
were initially not done. Subsequent CT scan demonstrated pelvic 
mass and biopsy proved recurrent squamous cell carcinoma of 
the rectum and vaginal cuff. She had diffuse metastatic disease to 
liver and retroperitoneum on CT at that time. As part of the initial 
treatment, the rectum and bladder received maximum doses of 
49 and 48  Gy, respectively. Three years later, SBRT delivered a 
maximum dose of 28.9  Gy to the bladder and 27.5  Gy to the 
rectum in five fractions. Since the toxicity occurred initially with 
no definite evidence of recurrent disease, we have reported this 
as radiation toxicity. However, we feel that this toxicity is most 
likely secondary to undiagnosed recurrent disease, which was 
ultimately discovered, and not SBRT.
DiscUssiOn
This study focuses on gynecologic cancer recurrence treated by 
SBRT in the most common sites of local/regional recurrence – 
namely the PSW, PA lymph node regions, and CP/vagina. By 
contrast, most comparable data sets include primary and recur-
rent gynecologic malignancies together or included gynecologic 
recurrence as a subset of multiple recurrent cancers treated by 
SBRT. Two Korean studies investigated the efficacy of SBRT 
for uterine cervical recurrences, one experience reflected the 
outcomes of PA lesions and the other reported on PSW lesions. 
Choi et al. reviewed 30 patients with PA recurrences treated with 
33–45  Gy in three fractions and described a 4-year LC rate of 
67.4% and median progression-free survival of 32 months (32). 
In the PSW study, the 2-year LC and OS rates were 65 and 43%, 
respectively (33). Kunos et al. published a phase II study of SBRT 
for gynecological recurrences, of which 33 patients had pelvic 
lesions. The treatment was 24 Gy in three fractions with a response 
rate of 68% and median OS of 20.2 months. The overall survival 
and LC results of this study are very similar to those reported by 
Choi, Seo, and Kunos, although some prognosticators differed.
Among the factors that influenced survival, PS and target 
volume were the strongest correlates, both of which were statisti-
cally significant with multivariate analysis. Older patients, lower 
BEDs, lack of salvage chemotherapy, or previously irradiated 
patients were more likely to have a worse survival in univariate 
analysis. Similar studies also found re-irradiation and larger 
FigUre 2 | (a) Kaplan–Meier survival curve separated by clinical target volume (CTV). Optimal CTV = 24 cc. (B) Kaplan–Meier survival curve separated by ECOG 
performance status.
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FigUre 3 | (a) Kaplan–Meier local control curve separated by tumor location. (B) Kaplan–Meier curve for local control separated by type of primary.
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TaBle 3 | Univariate analysis: local control hazard ratios (N = 35).
Prognostic factors N local control hr  
(95% ci)
p-Value
Serous/clear cell/carcinosarcoma 9 14.12 (2.86–69.54) 0.002
Cervical/endometrioid 26
SBRT alone 26 3.57 (0.045–28.6) 0.24
SBRT boost 9
Re-irradiation 15 0.56 (0.12–2.60) 0.46
No re-irradiation 20
ECOG 2 9 1.08 (0.11–10.49) 0.95
ECOG 0 9
ECOG 2 9 1.14 (0.14–9.18) 0.90
ECOG 1 17
Central pelvis 11 4.78 (1.26–18.18) 0.02
PA/PSW LN 24
CTV ≥ 30 cc 18 2.73 (0.57–13.05) 0.21
CTV < 30 cc 17
Time to recurrence ≥ 28 mo 15 2.35 (0.59–9.39) 0.23
Time to recurrence < 28 mo 15
Age ≥ 70 18 1.43 (0.38–5.30) 0.43
Age < 70 17
BED < 53.6 Gy 18 1.13 (0.31–4.21) 0.85
BED ≥ 53.6 Gy 17
Chemo for relapse 13 2.63 (0.54–12.5) 0.23
No chemo for relapse 21
Prior chemotherapy 9 1.19 (0.34–4.11) 0.78
No prior chemotherapy 21
CP, central pelvis; PA, para-aortic; PSW, pelvic sidewall; SBRT, stereotactic body 
radiation therapy; N, Number of lesions; HR, hazard ratio; CI, confidence interval.
Bold indicates statistical significance.
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targets to be poor prognosticators for survival, although the 
optimal cutoff size varies. A data set comprised of PSW recur-
rences delineated a cutoff size of GTV = 30 cc, whereas another 
study including just PA LN recurrences identified a PTV = 17 cc 
(32, 33). Our study found no distinction between CP, PAN, and 
PSW recurrence and found the optimal CTV to be less than or 
equal to 24 cc. Longer time to recurrence was commonly noted 
as a positive prognosticator for survival as well, although it was 
not a significant factor in our data. Pelvic recurrences treated 
with surgery, chemotherapy, or conventional radiation reported 
a better prognosis for central lesions compared to PSW or PA 
regions, although survival rates among those studies were poor 
overall (34–39). The current series is the first SBRT experience to 
report the effect of recurrence location on survival in gynecologic 
malignancies with no difference in survival between CP, PAN, or 
PSW recurrences. Likewise, type of primary did not affect sur-
vival, including the comparatively more aggressive ovarian and 
papillary serous uterine cancers compared to cervical cancers 
and endometrioid adenocarcinoma.
The 5-year LC rate of the entire patient population was 
67% and therefore median LC duration could not be obtained. 
Papillary serous (ovarian and uterine) and carcinosarcomatous 
tumors were more likely to recur locally compared to cervical 
and endometrioid types. Of the 12 cervical cancers included 
in the study, there were no local failures after SBRT. CP recur-
rences were also more likely to have a local recurrence following 
SBRT compared to PAN or PSW tumors. Other SBRT data 
reflects nearly identical LC rates for gynecologic recurrences, 
regardless of the location within the pelvis (32, 33). The lone 
predictor of local recurrence among those studies was tumor 
size which was significant for survival but not local recurrence 
in our database.
The toxicity profile among our patients is consistent with the 
literature, where every analogous study reports at least one grade 
3 or higher toxicity. Seven incidences of enterovaginal fistulas 
were described among four series (20, 24, 30, 33). Three of these 
were in the PSW recurrence study by Seo et al., who determined 
that a D5cc < 30 Gy, V40 < 50 cc, or a GTV < 50 cc drastically 
decreased the risk of developing a fistula (33). The lone fistula in 
our review was the result of 25 Gy in five fractions delivered to 
an 88.8 cc central recurrence following previous radical hysterec-
tomy and post-operative 45 Gy IMRT for the initial disease. It is 
questionable whether our lone grade 3 toxicity should be coded 
due to radiation since central disease recurrence was ultimately 
documented. All three significant late toxicities in our series were 
treated with SBRT for local recurrence adjacent to the rectum or 
bladder.
cOnclUsiOn
Although limited by a small patient population and the intrinsic 
selection bias of a retrospective review, our data corroborates the 
promising survival and control rates of pelvic and PA gynecologic 
recurrences treated by SBRT. The toxicity profile is low especially 
with PSW and PAN recurrence; however, caution should be 
used with bigger centrally recurring tumors as they are in close 
proximity to the rectum/bladder, increasing the risk for fistulas 
in particular if the target region received previous radiation. 
Retrospective series such as this one suggest that SBRT is emerging 
as the salvage therapy of choice for select recurrent gynecologic 
malignancies in the pelvis and PA region when brachytherapy 
is not possible. Prospective trials would help determine ideal 
patient selection to maximize efficacy and limit toxicity.
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